We are live on
!
Find out more
Corvus Pharmaceuticals
CRVS
CRVS
48 hedge funds and large institutions have $34.2M invested in Corvus Pharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 13 increasing their positions, 11 reducing their positions, and 7 closing their positions.
New
Increased
Maintained
Reduced
Closed
22% more capital invested
Capital invested by funds: $28M → $34.2M (+$6.21M)
18% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 11
0.47% more ownership
Funds ownership: 39.18% → 39.65% (+0.47%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
8% less funds holding
Funds holding: 52 → 48 (-4)
45% less call options, than puts
Call options by funds: $86K | Put options by funds: $157K
57% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 7
Holders
48
Holders Change
-4
Holders Change %
-7.69%
% of All Funds
0.7%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.01%
New
3
Increased
13
Reduced
11
Closed
7
Calls
$86K
Puts
$157K
Net Calls
-$71K
Net Calls Change
-$72K
Top Buyers
| 1 |
Morgan Stanley
New York
|
+$478K |
| 2 |
Renaissance Technologies
New York
|
+$242K |
| 3 |
TL
TowerView LLC
New York
|
+$138K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$135K |
| 5 |
SC
Samlyn Capital
New York
|
+$132K |
Top Sellers
| 1 |
Marshall Wace
London,
United Kingdom
|
-$289K |
| 2 |
Two Sigma Investments
New York
|
-$135K |
| 3 |
JP Morgan Chase
New York
|
-$101K |
| 4 |
Millennium Management
New York
|
-$98.2K |
| 5 |
Goldman Sachs
New York
|
-$72K |
